Apr, 2023

U.S.A.
News / Therapeutic Area News
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that The Lancet published detailed data from the Phase 3 SPOTLIGHT trial evaluating first-line...
Read More
U.S.A.
News / Therapeutic Area News
FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
– First treatment option combining an antibody-drug conjugate plus a PD-1 inhibitor in this patient population – TOKYO and BOTHELL, Wash., April 3, 2023 /PRNewswire/ -- Astellas Pharma Inc....
Read More

Mar, 2023

U.S.A.
News / Therapeutic Area News
Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series
Data shows investigational zolbetuximab plus CAPOX reduced risk of progression or death by 31.3% vs CAPOX alone Study evaluated patients with Claudin 18.2-positive, HER2-negative, locally advanced...
Read More
U.S.A.
News / Therapeutic Area News
Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet
Treatment with fezolinetant resulted in statistically significant reductions in the frequency and severity of VMS and improvements in quality of life TOKYO, March 13, 2023 /PRNewswire/ -- Astellas...
Read More
U.S.A.
News / Therapeutic Area News
Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
– Clinical data submitted are consistent with global data and support enfortumab vedotin as a platinum-free option in patients with locally advanced or metastatic urothelial cancer who received...
Read More